

Innovation all for the patients



CHUGAI PHARMABODY RESEARCH PTE. LTD.
INNOVATION BEGINS WITH ME





About CHUGAI PHARMABODY RESEARCH PTE. LTD. (CPR)

CPR was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, in January 2012. Our mission is to discover innovative solutions for unmet medical needs by creating new antibody and cyclic peptide drugs that can significantly improve patients' lives and contribute to the medical community around the world. CPR possesses all drug discovery research functions from lead identification and optimization to pharmacokinetics, pharmacology, and development of new technologies. By taking full advantage of Singapore's innovative environment for world-class biomedical research, highly trained and multi-national scientists and government support, we are now a global leader in the field of both antibody drug discovery and cyclic peptide drug discovery research.

Additional information is available at <https://www.chugai-pharmabody.com/>



Join us and be part of a Global Top Pharmaceutical Company

About OUR PEOPLE



132 Employees
8 Nationalities
Various Expertise
As at 31 January 2021



Work as a unified team
Committed to making the best
use of our R&D investments,
resources and talents



Acknowledging our people's contribution, no matter how small it is
Recognizing their efforts, not just by management but by each other
Trust, placing trust in our people to empower them



7th Anniversary celebration on board Royal Albatross, 2019

Sir David Lane, Chairman of the Board of CPR

CPR is proud to have Sir David Lane as Chairman of the Board. Sir David concurrently serves as Chief Scientist at the Agency for Science, Technology and Research (A*STAR). Sir David believes that CPR has a world leading drug discovery platform of antibody and cyclic peptide based drugs, and contributes to a community of innovation and generates a pipeline of products that will help patients around the world.

About CHUGAI PHARMACEUTICAL CO., LTD. (CHUGAI)

Chugai Pharmaceutical is leading research-based biopharmaceutical company whose headquarter is located in Tokyo, Japan. As an important member of the Roche Group (Basel, Switzerland), Chugai is actively involved in global R&D activities. Chugai has a track record of providing innovative products in various diseases to solve the unmet medical needs.


Additional information is available on the internet at <https://www.chugai-pharm.co.jp/english/>.



About OUR SCIENCE

CPR works on drug discovery in various disease indications with unmet medical needs, including oncology, inflammatory disease, fibrotic disease, and genetic disease, etc based on our proprietary global top level antibody engineering and cyclic peptide technology. Research into greater depths of disease biology enables us to develop new research concepts for innovative drug development.

Expanding drug target universe by technology




While druggable targets are limited with conventional antibody technology, our proprietary technologies enables us to expand the drug target universe, strongly differentiating from others. We can harness our unique antibody and cyclic peptide technologies to better understand disease biology and discover or invent an unprecedented mode of action of drug targets. We continuously develop new technologies by ourselves trying to open up new fields of drugs.

Our proprietary technologies expand the drug target universe


Recycling antibody® technology

allows single antibody molecule to bind to an antigen multiple times while conventional antibody can only bind to the antigen once¹⁾. Applied to FDA-approved product, satralizumab.




Bispecific antibody technology

allows antibody to bind to two different antigens, and enables unique mode of action that overcome various unmet medical need²⁾³⁾. Applied to FDA-approved product, emicizumab.




Switch antibody™ technology

allows antibody to specifically bind to the target antigen in the tumor microenvironment without detectable binding to the antigen in plasma and normal tissue⁴⁾.



Cyclic peptide technology allows targeting intracellular protein-protein interaction by oral administration.

Images created using Mol* should cite the PDB ID, the corresponding structure publication, Mol* (doi:10.2312/molva.20181103), and RCSB PDB. (PDB ID 1QNG)



Reference

- 1) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nat Biotechnol.* 2010, 1203-7.
- 2) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. *Nat Med.* 2012, 1570-4.
- 3) An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. *Sci Transl Med.* 2017, 9(410).
- 4) Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation. *Cancer Discovery.* 2020.

CPR Global Research and Development network



-  **CHUGAI PHARMABODY RESEARCH PTE. LTD.**
Singapore
-  **CHUGAI PHARMACEUTICAL CO., LTD**
Japan
-  **ROCHE**
Switzerland and Germany
-  **GENENTECH**
USA

Innovation all for the patients



CHUGAI PHARMABODY RESEARCH PTE. LTD.

3 Biopolis Drive, #07-11 to 16, Synapse, Singapore 138623

TEL: +65 6933 4888 • FAX: +65 6684 2257